CardioSource WorldNews December 2014 - Page 42

anticoagulation has come of age generation XARELTO ® SIX INDICATIONS STRONG To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled For the treatment of pulmonary embolism (PE) For the treatment of deep vein thrombosis (DVT) For the prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery IMPORTANT SAFETY INFORMATION (cont’d) CONTRAINDICATIONS Active pathological bleeding Severe hypersensitivity reaction to XARELTO® (eg, anaphylactic reactions) WARNINGS AND PRECAUTIONS Increased Risk of Thrombotic Events After Premature Discontinuation: Premature discontinuation of any oral anticoagulant, including XARELTO®, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from XARELTO® to warfarin in clinical trials in atrial fibrillation patients. If XARELTO® is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant. Risk of Bleeding: XARELTO® increases the risk of bleeding and can cause serious or fatal bleeding. Promptly evaluate any signs or symptoms of blood loss and consider the need for blood replacement. Discontinue XARELTO® in patients with active pathological hemorrhage. • A specific antidote for rivaro